● Recruiting

Evaluating the Safety and Efficacy of AMOR-1 as a Treatment for Hypocalcemia Associated With Hypoparathyroidism in Adults

Condition: Hypoparathyroidism · Sponsor: Amorphical Ltd.

PhasePhase 2

Planned participants81

Who can joinAll sexes, 18 Years to no upper limit

Healthy volunteersNo

About this study

This clinical trial aims to evaluate the efficacy and safety of AMOR-1, consisting of Amorphous Calcium Carbonate (ACC) as the active drug substance, in treating hypocalcemia in adults with hypoparathyroidism.

This description comes directly from the study's public registry record.

Talk to the study team

Study Coordinator - Rabin Medical Center · 972-3-9377182 · liatro3@clalit.org.il

Always discuss trial participation with your own doctor first.

Locations (8)

Assuta Ashdod medical center	Ashdod, Israel, Israel	Recruiting
Hadassah Ein Kerem Medical Center	Jerusalem, Israel, Israel	Recruiting
Rabin Medical Center, Belinson Campus	Petah Tikva, Israel, Israel	Recruiting
Barzilai Medical Center	Ashkelon, Israel	Active Not Recruiting
Soroka Medical Center	Beersheba, Israel	Recruiting
Rambam Medical Center	Haifa, Israel	Not Yet Recruiting
Sheba Medical Center	Ramat Gan, Israel	Recruiting
Kaplan Medical Center	Rehovot, Israel	Not Yet Recruiting

Follow this study

Get one email when the public record changes — results posted, or the study's status changes. Nothing else, ever.

We email about this public record only. Unsubscribe anytime with one click. Never medical advice.

Is this your study? This page was generated automatically from the public registry record. Sponsors can claim it — free — to add branding and verified contact routing. Claim this page →

This page is independently generated by Eichor from the public ClinicalTrials.gov record and re-synced daily. It is not the sponsor's official website unless claimed. Nothing here is medical advice; eligibility is always determined by the study team — talk to your own doctor first.

Source record: clinicaltrials.gov/study/NCT06547151